T2 Biosystems Reports Granting of Inducement Awards

LEXINGTON, Mass., May 03, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on May 1, 2018 it issued inducement awards to four new employees.   

These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides for the granting of equity awards to new employees of T2 Biosystems. The inducement awards consist of options to purchase 16,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $5.97, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on May 1, 2018. The options vest over a four-year period, with 25% vesting on the first anniversary of the employee’s date of hire and the remainder vesting in equal monthly installments over the three years thereafter. The award was approved by the independent compensation committee of T2 Biosystems’ board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4).   

About T2 Biosystems:
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of healthcare by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and the T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance technology, or T2MR®. T2Bacteria Panel is commercially available in Europe and other countries that accept the CE Mark and is available for research use only in the U.S. T2 Biosystems has an active pipeline of future products including additional species and antibiotic resistance for detection of sepsis pathogens, as well as tests for Lyme disease. For more information, please visit www.t2biosystems.com.

Media Contact:
Tom Langford, Feinstein Kean Healthcare
[email protected]
617-771-4510

Investor Contact:
Matthew Clawson, W2O Group
[email protected]
949-370-8500